{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:15:55Z","timestamp":1790486155909,"version":"4.1.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010449","name":"Nationales Centrum f\u00fcr Tumorerkrankungen Heidelberg","doi-asserted-by":"publisher","award":["G989"],"award-info":[{"award-number":["G989"]}],"id":[{"id":"10.13039\/501100010449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008658","name":"Deutsches Krebsforschungszentrum","doi-asserted-by":"publisher","award":["DKFZ International PhD Program"],"award-info":[{"award-number":["DKFZ International PhD Program"]}],"id":[{"id":"10.13039\/100008658","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ependymomas (EPN) are tumors of the central nervous system (CNS) that can arise in the supratentorial brain (ST-EPN), hindbrain or posterior fossa (PF-EPN) or anywhere in the spinal cord\u00a0(SP-EPN), both in children and adults. Molecular profiling studies have identified distinct groups and subtypes in each of these anatomical compartments. In this review, we give an overview on recent findings and new insights what is driving PFA ependymomas, which is the most common group. PFA ependymomas are characterized by a young median age at diagnosis, an overall balanced genome and a bad clinical outcome (56% 10-year overall survival). Sequencing studies revealed no fusion genes or other highly recurrently mutated genes, suggesting that the disease is epigenetically driven. Indeed, recent findings have shown that the characteristic global loss of the repressive histone 3 lysine 27 trimethylation (H3K27me3) mark in PFA ependymoma is caused by aberrant expression of the enhancer of zeste homolog inhibitory protein (EZHIP) or in rare cases by H3K27M mutations, which both inhibit EZH2 thereby preventing the polycomb repressive complex 2 (PRC2) from spreading H3K27me3. We present the current status of the ongoing work on EZHIP and its essential role in the epigenetic disturbance of PFA biology. Comparisons to the oncohistone H3K27M and its role in diffuse midline glioma (DMG) are drawn, highlighting similarities but also differences between the tumor entities and underlying mechanisms. A strong focus is to point out missing information and to present directions of further research that may result in new and improved therapies for PFA ependymoma patients.<\/jats:p>","DOI":"10.1007\/s00401-021-02382-4","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T10:02:26Z","timestamp":1636624946000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma"],"prefix":"10.1007","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2689-9937","authenticated-orcid":false,"given":"Anne","family":"Jenseit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Camg\u00f6z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan M.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Kool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"2382_CR1","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/dvdy.20577","volume":"234","author":"S Alam","year":"2005","unstructured":"Alam S, Zinyk D, Ma L, Schuurmans C (2005) Members of the Plag gene family are expressed in complementary and overlapping regions in the developing murine nervous system. Dev Dyn 234:772\u2013782. https:\/\/doi.org\/10.1002\/dvdy.20577","journal-title":"Dev Dyn"},{"key":"2382_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s40478-020-01056-8","volume":"8","author":"C Antin","year":"2020","unstructured":"Antin C, Tauzi\u00e8de-Espariat A, Debily MA, Castel D, Grill J, Pag\u00e8s M et al (2020) EZHIP is a specific diagnostic biomarker for posterior fossa ependymomas, group PFA and diffuse midline gliomas H3-WT with EZHIP overexpression. Acta Neuropathol Commun 8:183","journal-title":"Acta Neuropathol Commun"},{"key":"2382_CR3","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-1066","author":"A Arabzade","year":"2021","unstructured":"Arabzade A, Zhao Y, Varadharajan S, Chen H-C, Jessa S, Rivas B et al (2021) ZFTA-RELA dictates oncogenic transcriptional programs to drive aggressive supratentorial ependymoma. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.cd-20-1066","journal-title":"Cancer Discov"},{"key":"2382_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40478-016-0349-9","volume":"4","author":"A Araki","year":"2016","unstructured":"Araki A, Chocholous M, Gojo J, Dorfer C, Czech T, Heinzl H et al (2016) Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma. Acta Neuropathol Commun 4:88. https:\/\/doi.org\/10.1186\/s40478-016-0349-9","journal-title":"Acta Neuropathol Commun"},{"key":"2382_CR5","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.molcel.2017.10.025","volume":"68","author":"MB Ardehali","year":"2017","unstructured":"Ardehali MB, Anselmo A, Cochrane JC, Kundu S, Sadreyev RI, Kingston RE (2017) Polycomb repressive complex 2 methylates elongin a to regulate transcription. Mol Cell 68:872-884.e6. https:\/\/doi.org\/10.1016\/j.molcel.2017.10.025","journal-title":"Mol Cell"},{"key":"2382_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","volume":"24","author":"IM Bachmann","year":"2006","unstructured":"Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA et al (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24:268\u2013273. https:\/\/doi.org\/10.1200\/JCO.2005.01.5180","journal-title":"J Clin Oncol"},{"key":"2382_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab034","author":"L Baroni","year":"2021","unstructured":"Baroni L, Sundaresan L, Heled A, Coltin H, Pajtler KW, Lin T et al (2021) Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noab034","journal-title":"Neuro Oncol"},{"key":"2382_CR8","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1084\/jem.20181276","volume":"216","author":"F Basheer","year":"2019","unstructured":"Basheer F, Giotopoulos G, Meduri E, Yun H, Mazan M, Sasca D et al (2019) Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. J Exp Med 216:966\u2013981. https:\/\/doi.org\/10.1084\/jem.20181276","journal-title":"J Exp Med"},{"key":"2382_CR9","doi-asserted-by":"publisher","first-page":"366ra161","DOI":"10.1126\/scitranslmed.aah6904","volume":"8","author":"J Bayliss","year":"2016","unstructured":"Bayliss J, Mukherjee P, Lu C, Jain SU, Chung C, Martinez D et al (2016) Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Sci Transl Med 8:366ra161. https:\/\/doi.org\/10.1126\/scitranslmed.aah6904","journal-title":"Sci Transl Med"},{"key":"2382_CR10","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccr.2013.10.006","volume":"24","author":"S Bender","year":"2013","unstructured":"Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DTW, Kool M et al (2013) Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24:660\u2013672. https:\/\/doi.org\/10.1016\/j.ccr.2013.10.006","journal-title":"Cancer Cell"},{"key":"2382_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cell.2006.02.041","volume":"125","author":"BE Bernstein","year":"2006","unstructured":"Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J et al (2006) A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125:315\u2013326. https:\/\/doi.org\/10.1016\/j.cell.2006.02.041","journal-title":"Cell"},{"key":"2382_CR12","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s00381-009-0915-6","volume":"25","author":"E Bouffet","year":"2009","unstructured":"Bouffet E, Tabori U, Huang A, Bartels U (2009) Ependymoma: lessons from the past, prospects for the future. Child\u2019s Nerv Syst 25:1383\u20131384. https:\/\/doi.org\/10.1007\/s00381-009-0915-6","journal-title":"Child\u2019s Nerv Syst"},{"key":"2382_CR13","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00401-020-02142-w","volume":"139","author":"D Castel","year":"2020","unstructured":"Castel D, Kergrohen T, Tauzi\u00e8de-Espariat A, Mackay A, Ghermaoui S, Lechapt E et al (2020) Histone H3 wild-type DIPG\/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3\u2013K27M mutation. Acta Neuropathol 139:1109\u20131113. https:\/\/doi.org\/10.1007\/s00401-020-02142-w","journal-title":"Acta Neuropathol"},{"key":"2382_CR14","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1101\/gad.217778.113","volume":"27","author":"KM Chan","year":"2013","unstructured":"Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M et al (2013) The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 27:985\u2013990. https:\/\/doi.org\/10.1101\/gad.217778.113","journal-title":"Genes Dev"},{"key":"2382_CR15","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1158\/1541-7786.MCR-16-0389","volume":"15","author":"FJ Cordero","year":"2017","unstructured":"Cordero FJ, Huang Z, Grenier C, He X, Hu G, McLendon RE et al (2017) Histone H3.3K27M represses p16 to accelerate gliomagenesis in a murine model of DIPG. Mol Cancer Res 15:1243\u20131254. https:\/\/doi.org\/10.1158\/1541-7786.MCR-16-0389","journal-title":"Mol Cancer Res"},{"key":"2382_CR16","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/ijc.28440","volume":"134","author":"B Dewaele","year":"2014","unstructured":"Dewaele B, Przybyl J, Quattrone A, Finalet Ferreiro J, Vanspauwen V, Geerdens E et al (2014) Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma. Int J Cancer 134:1112\u20131122. https:\/\/doi.org\/10.1002\/ijc.28440","journal-title":"Int J Cancer"},{"key":"2382_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.86837","volume":"1","author":"D Djureinovic","year":"2019","unstructured":"Djureinovic D, Hallstr\u00f6m BM, Horie M, Margareta Mattsson JS, La FL, Fagerberg L et al (2019) Profiling cancer testis antigens in non-small-cell lung cancer. JCI Insight 1:1\u201318. https:\/\/doi.org\/10.1172\/jci.insight.86837","journal-title":"JCI Insight"},{"key":"2382_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W (2020) EZH2: a novel target for cancer treatment. J Hematol Oncol 13:104. https:\/\/doi.org\/10.1186\/s13045-020-00937-8","journal-title":"J Hematol Oncol"},{"key":"2382_CR19","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1126\/science.1253799","volume":"346","author":"K Funato","year":"2014","unstructured":"Funato K, Major T, Lewis PW, Allis CD, Tabar V (2014) Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science (80-) 346:1529\u20131533. https:\/\/doi.org\/10.1126\/science.1253799","journal-title":"Science (80-)"},{"key":"2382_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00401-018-1888-x","volume":"136","author":"FMG Cavalli","year":"2018","unstructured":"Cavalli FMG, H\u00fcbner J-M, Sharma T, Luu B, Sill M, Zapotocky M et al (2018) Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathol 136:227\u2013237. https:\/\/doi.org\/10.1007\/s00401-018-1888-x","journal-title":"Acta Neuropathol"},{"key":"2382_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0547-3","volume":"11","author":"L Gan","year":"2018","unstructured":"Gan L, Xu M, Hua R, Tan C, Zhang J, Gong Y et al (2018) The polycomb group protein EZH2 induces epithelial-mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter. J Hematol Oncol 11:1\u201312. https:\/\/doi.org\/10.1186\/s13045-017-0547-3","journal-title":"J Hematol Oncol"},{"key":"2382_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(13)70548-5","volume":"15","author":"G Gatta","year":"2014","unstructured":"Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J et al (2014) Childhood cancer survival in Europe 1999\u20132007: results of EUROCARE-5\u2014a population-based study. Lancet Oncol 15:35\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(13)70548-5","journal-title":"Lancet Oncol"},{"key":"2382_CR23","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00401-019-02056-2","volume":"138","author":"DR Ghasemi","year":"2019","unstructured":"Ghasemi DR, Sill M, Okonechnikov K, Korshunov A, Yip S, Schutz PW et al (2019) MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathol 138:1075\u20131089. https:\/\/doi.org\/10.1007\/s00401-019-02056-2","journal-title":"Acta Neuropathol"},{"key":"2382_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ccell.2020.06.004","volume":"38","author":"J Gojo","year":"2020","unstructured":"Gojo J, Englinger B, Jiang L, H\u00fcbner JM, Shaw ML, Hack OA et al (2020) Single-cell RNA-Seq reveals cellular hierarchies and impaired developmental trajectories in pediatric ependymoma. Cancer Cell 38:44-59.e9. https:\/\/doi.org\/10.1016\/j.ccell.2020.06.004","journal-title":"Cancer Cell"},{"key":"2382_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ccell.2021.01.005","volume":"39","author":"D Haag","year":"2021","unstructured":"Haag D, Mack N, Goncalves B, da Silva P, Statz B, Clark J et al (2021) H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model. Cancer Cell 39:407-422.e13. https:\/\/doi.org\/10.1016\/j.ccell.2021.01.005","journal-title":"Cancer Cell"},{"key":"2382_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.009","author":"J Han","year":"2020","unstructured":"Han J, Yu M, Bai Y, Yu J, Jin F, Li C et al (2020) Elevated CXorf67 expression in PFA ependymomas suppresses DNA repair and sensitizes to PARP inhibitors. Cancer Cell. https:\/\/doi.org\/10.1016\/j.ccell.2020.10.009","journal-title":"Cancer Cell"},{"key":"2382_CR27","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/neuonc\/noaa104","volume":"22","author":"C Hanna","year":"2020","unstructured":"Hanna C, Kurian KM, Williams K, Watts C, Jackson A, Carruthers R et al (2020) Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase i OPARATIC trial. Neuro Oncol 22:1840\u20131850. https:\/\/doi.org\/10.1093\/neuonc\/noaa104","journal-title":"Neuro Oncol"},{"key":"2382_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-09140-x","volume":"10","author":"AS Harutyunyan","year":"2019","unstructured":"Harutyunyan AS, Krug B, Chen H, Papillon-Cavanagh S, Zeinieh M, De Jay N et al (2019) H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2\/me3 and is essential for glioma tumorigenesis. Nat Commun 10:1\u201313. https:\/\/doi.org\/10.1038\/s41467-019-09140-x","journal-title":"Nat Commun"},{"key":"2382_CR29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1440-169x.2004.00762.x","volume":"46","author":"K Hensen","year":"2004","unstructured":"Hensen K, Braem C, Declercq J, Van Dyck F, Dewerchin M, Fiette L et al (2004) Targeted disruption of the murine Plag1 proto-oncogene causes growth retardation and reduced fertility. Dev Growth Differ 46:459\u2013470. https:\/\/doi.org\/10.1111\/j.1440-169x.2004.00762.x","journal-title":"Dev Growth Differ"},{"key":"2382_CR30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1081\/CNV-120001182","volume":"20","author":"JL Hess","year":"2002","unstructured":"Hess JL, Kossev P (2002) Molecular genetics of benign tumors. Cancer Invest 20:362\u2013372. https:\/\/doi.org\/10.1081\/CNV-120001182","journal-title":"Cancer Invest"},{"key":"2382_CR31","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/neuonc\/noz058","volume":"21","author":"JM H\u00fcbner","year":"2019","unstructured":"H\u00fcbner JM, M\u00fcller T, Papageorgiou DN, Mauermann M, Krijgsveld J, Russell RB et al (2019) EZHIP\/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma. Neuro Oncol 21:878\u2013889. https:\/\/doi.org\/10.1093\/neuonc\/noz058","journal-title":"Neuro Oncol"},{"key":"2382_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09981-6","author":"SU Jain","year":"2019","unstructured":"Jain SU, Do TJ, Lund PJ, Rashoff AQ, Diehl KL, Cieslik M et al (2019) PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-019-09981-6","journal-title":"Nat Commun"},{"key":"2382_CR33","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.molcel.2020.09.028","volume":"80","author":"SU Jain","year":"2020","unstructured":"Jain SU, Rashoff AQ, Krabbenhoft SD, Hoelper D, Do TJ, Gibson TJ et al (2020) H3 K27M and EZHIP impede H3K27-methylation spreading by inhibiting allosterically stimulated PRC2. Mol Cell 80:726-735.e7. https:\/\/doi.org\/10.1016\/j.molcel.2020.09.028","journal-title":"Mol Cell"},{"key":"2382_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/nature09173","author":"RA Johnson","year":"2010","unstructured":"Johnson RA, Wright KD, Poppleton H, Mohankumar KM, Finkelstein D, Pounds SB et al (2010) LETTERS Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature. https:\/\/doi.org\/10.1038\/nature09173","journal-title":"Nature"},{"key":"2382_CR35","doi-asserted-by":"publisher","first-page":"11316","DOI":"10.1038\/ncomms11316","volume":"7","author":"N Justin","year":"2016","unstructured":"Justin N, Zhang Y, Tarricone C, Martin SR, Chen S, Underwood E et al (2016) Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2. Nat Commun 7:11316. https:\/\/doi.org\/10.1038\/ncomms11316","journal-title":"Nat Commun"},{"key":"2382_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/neuonc\/nox149","volume":"20","author":"M Karremann","year":"2018","unstructured":"Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M et al (2018) Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro Oncol 20:123\u2013131. https:\/\/doi.org\/10.1093\/neuonc\/nox149","journal-title":"Neuro Oncol"},{"key":"2382_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/nan.12591","volume":"46","author":"LH Kasper","year":"2020","unstructured":"Kasper LH, Baker SJ (2020) Invited review: emerging functions of histone H3 mutations in paediatric diffuse high-grade gliomas. Neuropathol Appl Neurobiol 46:73\u201385. https:\/\/doi.org\/10.1111\/nan.12591","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2382_CR38","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00401-012-0998-0","volume":"124","author":"DA Khuong-Quang","year":"2012","unstructured":"Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124:439\u2013447. https:\/\/doi.org\/10.1007\/s00401-012-0998-0","journal-title":"Acta Neuropathol"},{"key":"2382_CR39","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1158\/1541-7786.MCR-08-0584","volume":"7","author":"J-P Kilday","year":"2009","unstructured":"Kilday J-P, Rahman R, Dyer S, Ridley L, Lowe J, Coyle B et al (2009) Pediatric ependymoma: biological perspectives. Mol Cancer Res 7:765\u2013786. https:\/\/doi.org\/10.1158\/1541-7786.MCR-08-0584","journal-title":"Mol Cancer Res"},{"key":"2382_CR40","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1158\/1078-0432.CCR-11-2489","volume":"18","author":"JP Kilday","year":"2012","unstructured":"Kilday JP, Mitra B, Domerg C, Ward J, Andreiuolo F, Osteso-Ibanez T et al (2012) Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective european clinical trial cohort analysis on behalf of the Children\u2019s Cancer Leukaemia Group (CCLG). Clin Cancer Res 18:2001\u20132011. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2489","journal-title":"Clin Cancer Res"},{"key":"2382_CR41","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1200\/JCO.2009.27.3359","volume":"28","author":"A Korshunov","year":"2010","unstructured":"Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M et al (2010) Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 28:3182\u20133190. https:\/\/doi.org\/10.1200\/JCO.2009.27.3359","journal-title":"J Clin Oncol"},{"key":"2382_CR42","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1126\/science.1232245","volume":"340","author":"PW Lewis","year":"2013","unstructured":"Lewis PW, M\u00fcller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA et al (2013) Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science (80-) 340:857\u2013861. https:\/\/doi.org\/10.1126\/science.1232245","journal-title":"Science (80-)"},{"key":"2382_CR43","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"2382_CR44","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature13108","volume":"506","author":"SC Mack","year":"2014","unstructured":"Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, St\u00fctz AM et al (2014) Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506:445\u2013450. https:\/\/doi.org\/10.1038\/nature13108","journal-title":"Nature"},{"key":"2382_CR45","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","volume":"32","author":"A Mackay","year":"2017","unstructured":"Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR et al (2017) Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 32:520-537.e5. https:\/\/doi.org\/10.1016\/j.ccell.2017.08.017","journal-title":"Cancer Cell"},{"key":"2382_CR46","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.cell.2020.04.047","volume":"181","author":"KA Michealraj","year":"2020","unstructured":"Michealraj KA, Kumar SA, Kim LJY, Cavalli FMG, Przelicki D, Wojcik JB et al (2020) Metabolic regulation of the epigenome drives lethal infantile ependymoma. Cell 181:1329-1345.e24. https:\/\/doi.org\/10.1016\/j.cell.2020.04.047","journal-title":"Cell"},{"key":"2382_CR47","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nature06008","volume":"448","author":"TS Mikkelsen","year":"2007","unstructured":"Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G et al (2007) Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448:553\u2013560. https:\/\/doi.org\/10.1038\/nature06008","journal-title":"Nature"},{"key":"2382_CR48","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nm.4293","volume":"23","author":"F Mohammad","year":"2017","unstructured":"Mohammad F, Weissmann S, Leblanc B, Pandey DP, H\u00f8jfeldt JW, Comet I et al (2017) EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med 23:483\u2013492. https:\/\/doi.org\/10.1038\/nm.4293","journal-title":"Nat Med"},{"key":"2382_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s10014-020-00385-9","author":"A Nabirajan","year":"2020","unstructured":"Nabirajan A, Sharma A, Rajeshwari M, Boorgula MT, Doddamani R, Garg A et al (2020) EZH2 inhibitory protein (EZHIP\/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations. Brain Tumor Pathol. https:\/\/doi.org\/10.1007\/s10014-020-00385-9","journal-title":"Brain Tumor Pathol"},{"key":"2382_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s10014-020-00385-9","volume":"38","author":"A Nambirajan","year":"2021","unstructured":"Nambirajan A, Sharma A, Rajeshwari M, Boorgula MT, Doddamani R, Garg A et al (2021) EZH2 inhibitory protein (EZHIP\/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations. Brain Tumor Pathol 38:30\u201340. https:\/\/doi.org\/10.1007\/s10014-020-00385-9","journal-title":"Brain Tumor Pathol"},{"key":"2382_CR51","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.trecan.2019.12.004","volume":"6","author":"J Ning","year":"2020","unstructured":"Ning J, Wakimoto H (2020) Therapeutic application of PARP inhibitors in neuro-oncology. Trends Cancer 6:147\u2013159. https:\/\/doi.org\/10.1016\/j.trecan.2019.12.004","journal-title":"Trends Cancer"},{"key":"2382_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-38510-0","volume":"9","author":"M Nomura","year":"2019","unstructured":"Nomura M, Saito K, Aihara K, Nagae G, Yamamoto S, Tatsuno K et al (2019) DNA demethylation is associated with malignant progression of lower-grade gliomas. Sci Rep 9:1\u201312. https:\/\/doi.org\/10.1038\/s41598-019-38510-0","journal-title":"Sci Rep"},{"key":"2382_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2651","author":"P Ntziachristos","year":"2012","unstructured":"Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Sol Flaherty M et al (2012) Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med. https:\/\/doi.org\/10.1038\/nm.2651","journal-title":"Nat Med"},{"key":"2382_CR54","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3892\/or.2014.3271","volume":"32","author":"TK Olsen","year":"2014","unstructured":"Olsen TK, Gorunova L, Meling TR, Micci F, Scheie D, Due-T\u00f8nnessen B et al (2014) Genomic characterization of ependymomas reveals 6q loss as the most common aberration. Oncol Rep 32:483\u2013490. https:\/\/doi.org\/10.3892\/or.2014.3271","journal-title":"Oncol Rep"},{"key":"2382_CR55","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nou223","volume":"16","author":"QT Ostrom","year":"2014","unstructured":"Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J et al (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007\u20132011. Neuro Oncol 16:iv1\u2013iv63. https:\/\/doi.org\/10.1093\/neuonc\/nou223","journal-title":"Neuro Oncol"},{"key":"2382_CR56","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00401-018-1877-0","volume":"136","author":"KW Pajtler","year":"2018","unstructured":"Pajtler KW, Wen J, Sill M, Lin T, Orisme W, Tang B et al (2018) Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol 136:211\u2013226. https:\/\/doi.org\/10.1007\/s00401-018-1877-0","journal-title":"Acta Neuropathol"},{"key":"2382_CR57","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","volume":"27","author":"KW Pajtler","year":"2015","unstructured":"Pajtler KW, Witt H, Sill M, Jones DTW, Hovestadt V, Kratochwil F et al (2015) Molecular classification of ependymal tumors across All CNS compartments, histopathological grades, and age groups. Cancer Cell 27:728\u2013743. https:\/\/doi.org\/10.1016\/j.ccell.2015.04.002","journal-title":"Cancer Cell"},{"key":"2382_CR58","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature13109","volume":"506","author":"M Parker","year":"2014","unstructured":"Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y et al (2014) C11orf95-RELA fusions drive oncogenic NF-\u03baB signalling in ependymoma. Nature 506:451\u2013455. https:\/\/doi.org\/10.1038\/nature13109","journal-title":"Nature"},{"key":"2382_CR59","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1200\/JCO.2011.35.5677","volume":"29","author":"BS Paugh","year":"2011","unstructured":"Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG et al (2011) Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 29:3999\u20134006. https:\/\/doi.org\/10.1200\/JCO.2011.35.5677","journal-title":"J Clin Oncol"},{"key":"2382_CR60","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1158\/0008-5472.CAN-13-1491","volume":"73","author":"BS Paugh","year":"2013","unstructured":"Paugh BS, Zhu X, Qu C, Endersby R, Diaz AK, Zhang J et al (2013) Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas. Cancer Res 73:6219\u20136229. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1491","journal-title":"Cancer Res"},{"key":"2382_CR61","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nm.4296","volume":"23","author":"A Piunti","year":"2017","unstructured":"Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA et al (2017) Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med 23:493\u2013500. https:\/\/doi.org\/10.1038\/nm.4296","journal-title":"Nat Med"},{"key":"2382_CR62","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax2887","author":"A Piunti","year":"2019","unstructured":"Piunti A, Smith ER, Morgan MAJ, Ugarenko M, Khaltyan N, Helmin KA et al (2019) Catacomb: an endogenous inducible gene that antagonizes H3K27 methylation activity of Polycomb repressive complex 2 via an H3K27M-like mechanism. Sci Adv. https:\/\/doi.org\/10.1126\/sciadv.aax2887","journal-title":"Sci Adv"},{"key":"2382_CR63","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40478-020-00905-w","volume":"8","author":"D Pratt","year":"2020","unstructured":"Pratt D, Quezado M, Abdullaev Z, Hawes D, Yang F, Garton HJL et al (2020) Diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymoma. Acta Neuropathol Commun 8:37. https:\/\/doi.org\/10.1186\/s40478-020-00905-w","journal-title":"Acta Neuropathol Commun"},{"key":"2382_CR64","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11060-014-1396-3","volume":"117","author":"E Purdy","year":"2014","unstructured":"Purdy E, Johnston DL, Bartels U, Fryer C, Carret AS, Crooks B et al (2014) Ependymoma in children under the age of 3 years: a report from the Canadian Pediatric Brain Tumour Consortium. J Neurooncol 117:359\u2013364. https:\/\/doi.org\/10.1007\/s11060-014-1396-3","journal-title":"J Neurooncol"},{"key":"2382_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-11800-x","volume":"10","author":"R Ragazzini","year":"2019","unstructured":"Ragazzini R, P\u00e9rez-Palacios R, Baymaz IH, Diop S, Ancelin K, Zielinski D et al (2019) EZHIP constrains Polycomb repressive complex 2 activity in germ cells. Nat Commun 10:1\u201318. https:\/\/doi.org\/10.1038\/s41467-019-11800-x","journal-title":"Nat Commun"},{"key":"2382_CR66","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s11060-015-2047-z","volume":"127","author":"M Rajeshwari","year":"2016","unstructured":"Rajeshwari M, Sharma MC, Kakkar A, Nambirajan A, Suri V, Sarkar C et al (2016) Evaluation of chromosome 1q gain in intracranial ependymomas. J Neurooncol 127:271\u2013278. https:\/\/doi.org\/10.1007\/s11060-015-2047-z","journal-title":"J Neurooncol"},{"key":"2382_CR67","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00381-017-3481-3","volume":"33","author":"S Ryall","year":"2017","unstructured":"Ryall S, Guzman M, Elbabaa SK, Luu B, Mack SC, Zapotocky M et al (2017) H3 K27M mutations are extremely rare in posterior fossa group A ependymoma. Child\u2019s Nerv Syst 33:1047\u20131051. https:\/\/doi.org\/10.1007\/s00381-017-3481-3","journal-title":"Child\u2019s Nerv Syst"},{"key":"2382_CR68","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/gtc.12718","volume":"24","author":"H Sakai","year":"2019","unstructured":"Sakai H, Fujii Y, Kuwayama N, Kawaji K, Gotoh Y, Kishi Y (2019) Plag1 regulates neuronal gene expression and neuronal differentiation of neocortical neural progenitor cells. Genes Cells 24:650\u2013666. https:\/\/doi.org\/10.1111\/gtc.12718","journal-title":"Genes Cells"},{"key":"2382_CR69","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00401-019-01975-4","volume":"137","author":"AB Silveira","year":"2019","unstructured":"Silveira AB, Kasper LH, Fan Y, Jin H, Wu G, Shaw TI et al (2019) H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. Acta Neuropathol 137:637\u2013655. https:\/\/doi.org\/10.1007\/s00401-019-01975-4","journal-title":"Acta Neuropathol"},{"key":"2382_CR70","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrclinonc.2014.163","volume":"12","author":"A Sonnenblick","year":"2015","unstructured":"Sonnenblick A, De Azambuja E, Azim HA, Piccart M (2015) An update on PARP inhibitors\u2014moving to the adjuvant setting. Nat Rev Clin Oncol 12:27\u201341. https:\/\/doi.org\/10.1038\/nrclinonc.2014.163","journal-title":"Nat Rev Clin Oncol"},{"key":"2382_CR71","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ccr.2012.08.024","volume":"22","author":"D Sturm","year":"2012","unstructured":"Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DTW, Konermann C et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425\u2013437. https:\/\/doi.org\/10.1016\/j.ccr.2012.08.024","journal-title":"Cancer Cell"},{"key":"2382_CR72","doi-asserted-by":"publisher","first-page":"37080","DOI":"10.18632\/oncotarget.26354","volume":"9","author":"K Sun","year":"2018","unstructured":"Sun K, Mikule K, Wang Z, Poon G, Vaidyanathan A, Smith G et al (2018) A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget 9:37080\u201337096. https:\/\/doi.org\/10.18632\/oncotarget.26354","journal-title":"Oncotarget"},{"key":"2382_CR73","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/jnen\/nlz064","volume":"78","author":"AA Swanson","year":"2019","unstructured":"Swanson AA, Raghunathan A, Jenkins RB, Messing-J\u00fcnger M, Pietsch T, Clarke MJ et al (2019) Spinal cord ependymomas with MYCN amplification show aggressive clinical behavior. J Neuropathol Exp Neurol 78:791\u2013797. https:\/\/doi.org\/10.1093\/jnen\/nlz064","journal-title":"J Neuropathol Exp Neurol"},{"key":"2382_CR74","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1101\/GAD.338681.120","volume":"34","author":"F Szulzewsky","year":"2020","unstructured":"Szulzewsky F, Arora S, Hoellerbauer P, King C, Nathan E, Chan M et al (2020) Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis. Genes Dev 34:1051\u20131064. https:\/\/doi.org\/10.1101\/GAD.338681.120","journal-title":"Genes Dev"},{"key":"2382_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2925","author":"KR Taylor","year":"2014","unstructured":"Taylor KR, Mackay A, Truffaux N, Butterfield YS, Morozova O, Philippe C et al (2014) Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet. https:\/\/doi.org\/10.1038\/ng.2925","journal-title":"Nat Genet"},{"key":"2382_CR76","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A et al (2015) Tissue-based map of the human proteome. Science (80-) 347:1260419\u20131260419. https:\/\/doi.org\/10.1126\/science.1260419","journal-title":"Science (80-)"},{"key":"2382_CR77","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nature01075","volume":"419","author":"S Varambally","year":"2002","unstructured":"Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624\u2013629. https:\/\/doi.org\/10.1038\/nature01075","journal-title":"Nature"},{"key":"2382_CR78","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/bpa.12042","volume":"23","author":"S Venneti","year":"2013","unstructured":"Venneti S, Garimella MT, Sullivan LM, Martinez D, Huse JT, Heguy A et al (2013) Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol 23:558\u2013564. https:\/\/doi.org\/10.1111\/bpa.12042","journal-title":"Brain Pathol"},{"key":"2382_CR79","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41586-019-1158-7","volume":"572","author":"MC Vladoiu","year":"2019","unstructured":"Vladoiu MC, El-Hamamy I, Donovan LK, Farooq H, Holgado BL, Sundaravadanam Y et al (2019) Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature 572:67\u201373. https:\/\/doi.org\/10.1038\/s41586-019-1158-7","journal-title":"Nature"},{"key":"2382_CR80","doi-asserted-by":"publisher","first-page":"652","DOI":"10.7150\/ijbs.19108","volume":"13","author":"Y Wang","year":"2017","unstructured":"Wang Y, Hou N, Cheng X, Zhang J, Tan X, Zhang C et al (2017) Ezh2 acts as a tumor suppressor in kras-driven lung adenocarcinoma. Int J Biol Sci 13:652\u2013659. https:\/\/doi.org\/10.7150\/ijbs.19108","journal-title":"Int J Biol Sci"},{"key":"2382_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-020-0871-6","volume":"22","author":"K Wierzbicki","year":"2020","unstructured":"Wierzbicki K, Ravi K, Franson A, Bruzek A, Cantor E, Harris M et al (2020) Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma. Curr Oncol Rep 22:1\u20139","journal-title":"Curr Oncol Rep"},{"key":"2382_CR82","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ccr.2011.07.007","volume":"20","author":"H Witt","year":"2011","unstructured":"Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R et al (2011) Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20:143\u2013157. https:\/\/doi.org\/10.1016\/j.ccr.2011.07.007","journal-title":"Cancer Cell"},{"key":"2382_CR83","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ng.1102","volume":"44","author":"G Wu","year":"2012","unstructured":"Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44:251\u2013253. https:\/\/doi.org\/10.1038\/ng.1102","journal-title":"Nat Genet"},{"key":"2382_CR84","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ng.2938","volume":"46","author":"G Wu","year":"2014","unstructured":"Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y et al (2014) The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 46:444\u2013450. https:\/\/doi.org\/10.1038\/ng.2938","journal-title":"Nat Genet"},{"key":"2382_CR85","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/neuonc\/now016","volume":"18","author":"J Wu","year":"2016","unstructured":"Wu J, Armstrong TS, Gilbert MR (2016) Biology and management of ependymomas. Neuro Oncol 18:902\u2013913. https:\/\/doi.org\/10.1093\/neuonc\/now016","journal-title":"Neuro Oncol"},{"key":"2382_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105780","volume":"171","author":"W Wu","year":"2021","unstructured":"Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L et al (2021) Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res 171:105780. https:\/\/doi.org\/10.1016\/j.phrs.2021.105780","journal-title":"Pharmacol Res"},{"key":"2382_CR87","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.neo.2020.06.009","volume":"22","author":"Y Xiong","year":"2020","unstructured":"Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y et al (2020) Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia (US) 22:431\u2013440. https:\/\/doi.org\/10.1016\/j.neo.2020.06.009","journal-title":"Neoplasia (US)"},{"key":"2382_CR88","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/neuonc\/noy146","volume":"21","author":"AS Yamashita","year":"2019","unstructured":"Yamashita AS, Da Costa RM, Borodovsky A, Festuccia WT, Chan T, Riggins GJ (2019) Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide. Neuro Oncol 21:189\u2013200. https:\/\/doi.org\/10.1093\/neuonc\/noy146","journal-title":"Neuro Oncol"},{"key":"2382_CR89","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1002\/cncr.31995","volume":"125","author":"M Zapotocky","year":"2019","unstructured":"Zapotocky M, Beera K, Adamski J, Laperierre N, Guger S, Janzen L et al (2019) Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: cure at a cost. Cancer 125:1867\u20131876. https:\/\/doi.org\/10.1002\/cncr.31995","journal-title":"Cancer"},{"key":"2382_CR90","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-0963","author":"T Zheng","year":"2021","unstructured":"Zheng T, Ghasemi DR, Okonechnikov K, Korshunov A, Sill M, Maass KK et al (2021) Cross-species genomics reveals oncogenic dependencies in ZFTA\/C11orf95 fusion-positive supratentorial ependymomas. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.cd-20-0963","journal-title":"Cancer Discov"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-021-02382-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-021-02382-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-021-02382-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T11:10:31Z","timestamp":1641381031000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-021-02382-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2382"],"URL":"https:\/\/doi.org\/10.1007\/s00401-021-02382-4","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,11]]},"assertion":[{"value":"9 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}